Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites

Eckelman, William C.; Jones, Alun G.; Duatti, Adriano; Reba, Richard C.

doi:10.1016/j.drudis.2013.06.008

Cited by 27 publications

(39 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 10,000 hospitals worldwide use radiopharmaceuticals, of which more than 90% use them for diagnostic purposes [41]. Both PET and single-photon emission computed tomography (SPECT) require a radiopharmaceutical to be injected into the body before scanning.…”

Section: Nuclear Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Translational Imaging for Regenerative Medicine

Kelkar

Mohs

2015

Translational Regenerative Medicine

View full text Add to dashboard Cite

Section: Nuclear Imagingmentioning

confidence: 99%

“…SPECT radionuclides can be labeled to different molecules to image various targets simultaneously, for example, the 99m Tc-labeled tropane derivative [ 99m Tc] TRODAT-1 for dopamine transporter (DAT) imaging [41], [ 111 In]-labeled DTPA-octreotide for somatostatin receptor imaging, and [ 99m Tc] annexin-V for apoptosis imaging [49].…”

Section: Nuclear Imagingmentioning

confidence: 99%

Translational Imaging for Regenerative Medicine

Kelkar

Mohs

2015

Translational Regenerative Medicine

View full text Add to dashboard Cite

“…A paradigm shift is required to move from a slightly lower-affinity constant to be sensitive to changes in the b adrenoceptor as a function of disease and treatment to one that achieves a high target-to-nontarget ratio in order to detect abnormalities smaller than twice the instrument resolution (13). Another important paradigm shift is the evaluation of the clinical need.…”

Section: Biologymentioning

confidence: 99%

Chemistry and Biology of Radiotracers That Target Changes in Sympathetic and Parasympathetic Nervous Systems in Heart Disease

Eckelman

Dilsizian

2015

J Nucl Med

Self Cite

View full text Add to dashboard Cite

Following the discovery of the sympathetic and parasympathetic nervous system, numerous adrenoceptor drugs were radiolabeled and potent radioligands were prepared in order to image the β-adrenergic and the muscarinic systems. But the greatest effort has been in preparing noradrenaline analogs, such as norepinephrine, 11 C-metahydroxyephedrine, and 123 I-metaiodobenzylguanidine that measure cardiac sympathetic nerve varicosities. Given the technical and clinical challenges in designing and validating targeted adrenoceptor-binding radiotracers, namely the heavily weighted flow dependence and relatively low target-to-background ratio, both requiring complicated mathematic analysis, and the inability of targeted adrenoceptor radioligands to have an impact on clinical care of heart disease, the emphasis has been on radioligands monitoring the norepinephrine pathway. The chemistry and biology of such radiotracers, and the clinical and prognostic impact of these innervation imaging studies in patients with heart disease, are examined.

show abstract

“…Persentase rendemen 99m Tc yang dihasilkan oleh MBZ berkisar antara 5-80% dan cenderung rendah. Hal ini akan membuat generator 99 Mo/ 99m Tc sulit digunakan karena konsentrasi 99m Tc yang dihasilkan tidak bisa diprediksi dan beberapa farmaka membutuhkan radioaktivitas 99m Tc yang tinggi [16,17].…”

unclassified